This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ATC, BCH-10652; SPD754; AVX-301, AVX754
Description: Apricitabine (SPD754) belongs to the class of anti-HIV drugs known as nucleoside analogue reverse transcriptase inhibitors (NRTIs). Like other NRTIs, apricitabine interferes with the process of HIV replication by imitating the nucleosides or building blocks of DNA, used to produce new HIV genetic material.
Avexa and Shire
In January 2005, Shire Pharmaceuticals Group plc out-licensed SPD754 to Avexa Limited. Avexa will take on full responsibility for the worldwide development of SPD754 in accordance with an agreed development plan. Avexa has the right to commercialize SPD754 throughout the world, excluding North America (USA and Canada), where Shire retains the right to commercialize the product. An undisclosed reciprocal royalty will be payable. Included in the deal and subject to subsequent satisfaction of certain conditions, Shire will take a AUD$2 million equity position in Avexa, subject to Avexa shareholder approval, and will also have an option to acquire four million more shares following the successful completion of the Phase IIb trial.
In January 2007, Shire announced that it licensed the North America (U.S. and Canada) rights for Apricitabine (SPD754, AVX754), to Avexa in return for an up-front payment of US$10 million, development and sales related milestones...See full deal structure in Biomedtracker
Partners: Shire Pharmaceuticals Group PLC Link Healthcare Pte Ltd.
Additional information available to subscribers only: